Found 6 articles
ARKAY Therapeutics Announced as a Finalist in Most Successful Early Phase Research in 2019 Clinical & Research Excellence Awards
ARKAY Therapeutics has been named a finalist in the Most Successful Early Phase Research (Preclinical and Phase I) category in the CARE Awards, which recognize outstanding work across the global clinical research enterprise.
The U.S. FDA Approves ARKAY Therapeutics’ IND Application for Evaluating RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product in Type 2 Diabetes Patients
Human Proof-of-Concept (PoC) Trial to Evaluate the Superiority of RK-01 Over Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control.
ARKAY Therapeutics Submits Investigational New Drug (IND) Application for RK-01, a First-in Class ‘Beta-cell-centric’ Drug Combination Product for Type 2 Diabetes
First Human Proof-of-Concept (PoC) Trial to Test the Superiority of RK-01 over Metformin in Type 2 Diabetes Patients with Inadequate Glycemic Control.
ARKAY Therapeutics’ Announces Notice Of Allowance Of Patent Application For First-In Class “Beta-Cell-Centric” Drug, RK-01 For Type 2 Diabetes From The United States Patent Office
Renowned Endocrinologist, Dr. Stan Schwartz, Regulatory Strategies Expert Dr. Nancy Motola And Formulations Expert, Dr. Hemant Joshi Join ARKAY Therapeutics’ Scientific Advisory Board